newsio aggregates and links to original sources. We do not own the original images or content. If you believe content infringes on intellectual property rights, contact us — it will be removed at first notice.

business / news / / Seeking Alpha

Biogen to buy China rights to immune disease drug for up to $850M.

Biogen will acquire exclusive Greater China rights for felzartamab from TJ Bio.

KEY POINTS
COMPANIES
Read the full story on Seeking Alpha →
Share X LinkedIn

Summarized by Newsio from Seeking Alpha. How we summarize →